五氟化(4-氰苯基)硫 | 401892-85-1

• 物质功能分类: 有机原料 - 有机氟化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 五氟化(4-氰苯基)硫
• 中文别名: 4-五氟硫代苯甲腈
• 英文名称: 4-(pentafluorosulfanyl)benzonitrile
• 英文别名: 4-(pentafluoro-λ6-sulfanyl)benzonitrile
• CAS: 401892-85-1
• 化学式: C₇H₄F₅NS
• mdl: MFCD03788521
• 分子量: 229.173
• InChiKey: SGACKKUEROEDNX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  24.8
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 危险等级：
  6.1
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P260,P264,P270,P271,P280,P301+P310,P302+P352,P304+P340,P311,P312,P321,P322,P330,P361,P363,P403+P233,P405,P501
• 危险品运输编号：
  3439
• 危险性描述：
  H301,H311,H331

反应信息

• 作为反应物：
  描述：

  五氟化(4-氰苯基)硫 在 Woollins 试剂 、 水 作用下， 以 甲苯 为溶剂， 反应 9.0h， 以87%的产率得到4-pentafluorosulfanylbenzoselenoamide
  参考文献：
  名称：

  2,4-Diaryl-1,3-Chalcogen Azoles Bearing Pentafluorosulfanyl SF₅Groups: A Synthetic and Structural Study

  摘要：

  A series of new 2,4-diaryl-1,3-chalcogen azoles having pentafluorosulfanyl SF5 functional groups has been prepared by means of the two-component cyclization of the selenoamide or thioamide with alpha-bromoketones. The selenoamides or thioamides were obtained from the reaction of Woollins' reagent or Lawesson's reagent with 4-pentafluorosulfanylbenzonitrile, followed by hydrolysis with water. All new compounds were characterised by H-1, C-13, Se-77, F-19 NMR spectroscopy and accurate mass measurement. X-ray crystal structure analysis of the selenoamide, thioamide and 2,4-diarylpentafluorosulfanyl-1,3-chalcogen azoles reveal that the selenoamide and thioamide have very similar structural features along with similar intermolecular interactions such as the pi-pi stacking and the weak N-H center dot center dot center dot E (E = S or Se) hydrogen bonding. The 2,4-diarylpentafluorosulfanyl-1,3-chalcogen azoles show the newly formed five-membered N(1)-C(2)-E(3)-C(4)-C(5) ring is either perfectly planar (and coplanar with two peripheral aryl ring planes) or near-planar. The pi-pi intermolecular interactions and the weak C-H center dot center dot center dot pi and C-H center dot center dot center dot X (X = Br, F, O) hydrogen bonding are discussed in the cases of 2,4-diarylpentafluorosulfanyl-1,3-chalcogen azoles.

  DOI：

  10.1021/jo500316v
• 作为产物：
  描述：

  4-(五氟硫代)苯甲醛 在 盐酸羟胺 、 2,4,6-triphenylpyrylium tetrafluoroborate 作用下， 以 乙腈 为溶剂， 40.0 ℃ 、100.0 kPa 条件下， 反应 24.0h， 以85%的产率得到五氟化(4-氰苯基)硫
  参考文献：
  名称：

  可见光促进 C(sp3)−H 键无金属合成（杂）芳香腈**

  摘要：

  C(sp 3 )−H 键的无金属活化生成增值产品在有机合成中至关重要。我们报道了使用市售有机染料 2,4,6-三苯基吡喃鎓四氟硼酸盐 (TPP) 通过光催化过程将甲基芳烃转化为相应的芳基腈。应用这种方法，在不含金属和氰化物的条件下，可以以良好到优异的产率合成多种氰基苯。我们通过 50 多个示例证明了该方法的范围，包括药物分子（塞来昔布）的后期功能化和l-薄荷醇、氨基酸和胆固醇衍生物等复杂结构。此外，所提出的合成方案适用于克级反应。除了甲基芳烃之外，还展示了醛、醇和肟氰化的选定示例。使用时间分辨发光猝灭研究、控制实验、核磁共振波谱以及动力学研究进行了详细的机理研究，所有这些都支持了所提出的催化循环。

  DOI：

  10.1002/anie.202011815

文献信息

• HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS
  申请人：Härter Michael

  公开号：US20110301122A1

  公开（公告）日：2011-12-08

  The present application relates to novel substituted aryl compounds, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.

  本申请涉及新型取代芳基化合物，其制备方法，它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防过度增殖和血管生成性疾病以及那些由于代谢适应缺氧状态而引起的疾病。这种治疗可以作为单独治疗进行，也可以与其他药物或进一步的治疗措施结合使用。
• Aryl compounds with aminoalkyl substituents and their use
  申请人：Härter Michael

  公开号：US20110312930A1

  公开（公告）日：2011-12-22

  The present application relates to novel aryl compounds with aminoalkyl substituents, to processes for their preparation, to their use for treatment and/or prevention of diseases and to their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.

  本申请涉及具有氨基烷基取代基的新型芳基化合物，涉及其制备方法，涉及它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防过度增殖和血管生成性疾病以及那些由于代谢适应低氧状态而引起的疾病。这种治疗可以作为单独治疗进行，也可以与其他药物或进一步的治疗措施结合使用。
• Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation
  作者：Barbara Vergani、Giovanni Sandrone、Mattia Marchini、Chiara Ripamonti、Edoardo Cellupica、Elisabetta Galbiati、Gianluca Caprini、Gianfranco Pavich、Giulia Porro、Ilaria Rocchio、Maria Lattanzio、Marcello Pezzuto、Malgorzata Skorupska、Paola Cordella、Paolo Pagani、Pietro Pozzi、Roberta Pomarico、Daniela Modena、Flavio Leoni、Raffaella Perego、Gianluca Fossati、Christian Steinkühler、Andrea Stevenazzi

  DOI：10.1021/acs.jmedchem.9b01194

  日期：2019.12.12

  Histone deacetylase 6 (HDAC6) is a peculiar HDAC isoform whose expression and functional alterations have been correlated with a variety of pathologies such as autoimmune disorders, neurodegenerative diseases, and cancer. It is primarily a cytoplasmic protein, and its deacetylase activity is focused mainly on nonhistone substrates such as tubulin, heat shock protein (HSP)90, Foxp3, and cortactin, to

  组蛋白脱乙酰基酶6（HDAC6）是一种特殊的HDAC亚型，其表达和功能改变已与多种病理学相关，例如自身免疫性疾病，神经退行性疾病和癌症。它主要是一种细胞质蛋白，其脱乙酰酶活性主要集中在非组蛋白底物上，例如微管蛋白，热休克蛋白（HSP）90，Foxp3和cortactin等。HDAC6的选择性抑制在健康细胞中不显示细胞毒性作用，通常与I类HDAC同工型的抑制有关。在这里，我们描述了带有五杂环中央核心的新型有效和选择性HDAC6抑制剂的设计和合成。
• HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS
  申请人：Härter Michael

  公开号：US20130196964A1

  公开（公告）日：2013-08-01

  The present application relates to novel aryl compounds with heterocyclic substituents, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.

  本申请涉及具有杂环取代基的新型芳基化合物，其制备方法，它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防过度增殖和血管生成性疾病以及那些由于代谢适应缺氧状态而引起的疾病。这种治疗可以作为单独治疗进行，也可以与其他药物或进一步治疗措施结合使用。
• 4-(Pentafluorosulfanyl)benzenediazonium Tetrafluoroborate: A Versatile Launch Pad for the Synthesis of Aromatic SF₅Compounds via Cross Coupling, Azo Coupling, Homocoupling, Dediazoniation, and Click Chemistry
  作者：Takao Okazaki、Kenneth K. Laali、Scott D. Bunge、Sonya K. Adas

  DOI：10.1002/ejoc.201301538

  日期：2014.3

  4-trimethoxybenzene, aniline and phenol). Fluorodediazoniation in [BMIM][PF6] and [BMIM][BF4] selectively furnished the fluoro derivative p-SF5–C6H4F. Dediazoniation in [BMIM][NTf2] gave p-SF5–C6H4OS(O)(CF3)=NSO2CF3 as the major and p-SF5–C6H4-NTf2 as the minor products. Homolytic dediazoniation in MeCN/NaI gave the unsymmetrical biaryls p-SF5–C6H4-Ar (ArH = mesitylene and p-xylene) along with p-SF5–C6H4I

  首次合成并分离出4-(五氟硫烷基)苯重氮四氟硼酸盐试剂(1)，为稳定盐；随后研究了它在各种变换中的应用。通过采用 Heck-Matsuda、Sonogashira 和 Suzuki 偶联方案合成了一系列新型含 SF5 的烯烃、炔烃和联芳基衍生物。在 [BMIM][BF4] 中用 TMSX（X = Hal；N3；和 CN）和 NH4SCN 作为溶剂进行脱重氮作用，得到相应的 p-SF5–C6H4X 衍生物。叠氮化物衍生物 p-SF5–C6H4N3 与苯乙炔进行点击化学反应以提供相应的三唑。4,4'-双(五氟硫烷基)联苯通过使用Pd(OAc)2的均偶联合成。通过偶氮偶联反应性芳香亲核试剂获得相应的偶氮化合物 (1, 3-二甲氧基苯、1,3,5-三甲氧基苯、1,2,4-三甲氧基苯、苯胺和苯酚）。[BMIM][PF6] 和 [BMIM][BF4] 中的氟重氮作用选择性地提供了氟衍生物 p-SF5–C6H4F。[BMIM][NTf2]